The design of our phase 1 study was only designed for stroke patients not TBI
Phase 1 is to determine not only safety but also dose concentrations for that specific condition. You don’t just go into phase 2 guessing the dose we want to give. Phase 1 determines that and through blood markers
Looking back at our announcements it was all designed for stroke.
The design of our phase 1 study was only designed for stroke...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.0¢ |
Change
0.020(2.47%) |
Mkt cap ! $105.5M | |||
| Open | High | Low | Value | Volume |
| 82.5¢ | 83.0¢ | 81.0¢ | $37.30K | 45.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.5¢ | 15000 | 1 |
View Market Depth
| Last trade - 10.46am 12/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |